» Articles » PMID: 34769099

Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy Against Human Malignancies

Abstract

As a multifactorial disease, treatment of cancer depends on understanding unique mechanisms involved in its progression. The cancer stem cells (CSCs) are responsible for tumor stemness and by enhancing colony formation, proliferation as well as metastasis, and these cells can also mediate resistance to therapy. Furthermore, the presence of CSCs leads to cancer recurrence and therefore their complete eradication can have immense therapeutic benefits. The present review focuses on targeting CSCs by natural products in cancer therapy. The growth and colony formation capacities of CSCs have been reported can be attenuated by the dietary agents. These compounds can induce apoptosis in CSCs and reduce tumor migration and invasion via EMT inhibition. A variety of molecular pathways including STAT3, Wnt/β-catenin, Sonic Hedgehog, Gli1 and NF-κB undergo down-regulation by dietary agents in suppressing CSC features. Upon exposure to natural agents, a significant decrease occurs in levels of CSC markers including CD44, CD133, ALDH1, Oct4 and Nanog to impair cancer stemness. Furthermore, CSC suppression by dietary agents can enhance sensitivity of tumors to chemotherapy and radiotherapy. In addition to in vitro studies, as well as experiments on the different preclinical models have shown capacity of natural products in suppressing cancer stemness. Furthermore, use of nanostructures for improving therapeutic impact of dietary agents is recommended to rapidly translate preclinical findings for clinical use.

Citing Articles

OCT4 promotes lung cancer progression through upregulation of VEGF-correlated chemokine-1.

Su B, Wang C, Chang J, Chen H, Huang T, Yen Y Int J Med Sci. 2025; 22(3):680-695.

PMID: 39898238 PMC: 11783078. DOI: 10.7150/ijms.102505.


L. fruit peels show anti-cancer effects in preclinical models of breast carcinoma: The perspectives in the chemoprevention and therapy modulation.

Dvorska D, Mazurakova A, Lackova L, Sebova D, Kajo K, Samec M Front Oncol. 2024; 14:1463656.

PMID: 39435289 PMC: 11491292. DOI: 10.3389/fonc.2024.1463656.


DNA methylation biomarkers for predicting lymph node metastasis in colorectal cancer.

Sun Y, Kong D, Zhang Q, Xiang R, Lu S, Feng L Clin Transl Oncol. 2024; 27(2):439-448.

PMID: 39026026 DOI: 10.1007/s12094-024-03601-6.


Innovative Strategies to Combat 5-Fluorouracil Resistance in Colorectal Cancer: The Role of Phytochemicals and Extracellular Vesicles.

Barathan M, Zulpa A, Ng S, Lokanathan Y, Ng M, Law J Int J Mol Sci. 2024; 25(13).

PMID: 39000577 PMC: 11242358. DOI: 10.3390/ijms25137470.


L. exerts oncostatic effects in rodent and models of breast carcinoma.

Kubatka P, Mazurakova A, Koklesova L, Kuruc T, Samec M, Kajo K Front Pharmacol. 2024; 15:1216199.

PMID: 38464730 PMC: 10921418. DOI: 10.3389/fphar.2024.1216199.


References
1.
Wang N, Wang Z, Peng C, You J, Shen J, Han S . Dietary compound isoliquiritigenin targets GRP78 to chemosensitize breast cancer stem cells via β-catenin/ABCG2 signaling. Carcinogenesis. 2014; 35(11):2544-54. DOI: 10.1093/carcin/bgu187. View

2.
Ong P, Wang L, Dai X, Tseng S, Loo S, Sethi G . Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol. 2016; 7:395. PMC: 5079084. DOI: 10.3389/fphar.2016.00395. View

3.
Abadi A, Mirzaei S, Khaksary Mahabady M, Hashemi F, Zabolian A, Hashemi F . Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects. Phytother Res. 2021; 36(1):189-213. DOI: 10.1002/ptr.7305. View

4.
Hermawan A, Ikawati M, Khumaira A, Putri H, Jenie R, Angraini S . Bioinformatics and Studies Reveal the Importance of p53, PPARG and Notch Signaling Pathway in Inhibition of Breast Cancer Stem Cells by Hesperetin. Adv Pharm Bull. 2021; 11(2):351-360. PMC: 8046396. DOI: 10.34172/apb.2021.033. View

5.
Cao J, Bhatnagar S, Wang J, Qi X, Prabha S, Panyam J . Cancer stem cells and strategies for targeted drug delivery. Drug Deliv Transl Res. 2020; 11(5):1779-1805. PMC: 8062588. DOI: 10.1007/s13346-020-00863-9. View